The Effect of Erythropoietin at the Time of Reperfusion in Acute Myocardial Infarction

Phase 4 Study of the Effect of Human Recombinant Erythropoietin at the Time of Reperfusion in Patients With Acute Myocardial Infarction

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00882466

Enrollment

Registered

2009-04-16

Start date

2008-05-31

Completion date

2009-02-28

Last updated

2009-04-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Myocardial Infarction

Keywords

erythropoietin

Brief summary

The purpose of this study is to investigate the effect of intravenous human recombinant erythropoietin on the reperfusion injury at primary percutaneous coronary intervention in patients with acute myocardial infarction.

Interventions

DRUGhuman recombinant erythropoietin

intravenous bolus injection of EPO (50unit/kg)

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Acute myocardial infarction \<12hr * Age \>18yrs * First myocardial infarction * culprit lesion : proximal to mid left anterior descending artery * Baseline coronary flow : TIMI Grade 0\ 1

Exclusion criteria

* Patients with previous myocardial infarction * History of thrombotic complication * History of cerebral infarction * Uncontrolled hypertension * Increased hemoglobin level \>17g/dL * Patients with mechanical valve * Cardiogenic shock

Design outcomes

Primary

Measure	Time frame
Creatinine kinase (CK), creatinine kinase-MB (CK-MB)	4hr, 8hr, 12hr, 24hr, 48hr, 72hr

Secondary

Measure	Time frame
Infarct size assessed by cardiac MRI	day 4

Countries

South Korea

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Apr 1, 2026